Literature DB >> 20599474

Cerebrospinal fluid profile of amyloid β42 (Aβ42), hTau and ubiquitin in North Indian Alzheimer's disease patients.

Ramesh Jl Kandimalla1, Prabhakar S, Binukumar Bk, Willayat Yousuf Wani, Deep Raj Sharma, V K Grover, Neerja Bhardwaj, Kajal Jain, Kiran Dip Gill.   

Abstract

Alzheimer's disease (AD) is the most common form of dementia, and is characterized by the degeneration of neurons and their synapses, and a higher number of amyloid plaques and neurofibrillary tangles (NFTs) compared with that found in non-demented individuals. Amyloid-β-peptides (Aβ) are major components of amyloid plaques in AD brain whereas NFTs are composed of Tau and associated with ubiquitin. The aim of the present study was to analyze the levels of Aβ42, hTau (total Tau) and ubiquitin in CSF of North Indian population. CSF Aβ42, Tau and ubiquitin were measured in CSF of AD patients as well as controls using ELISA assays. Here we report low Aβ42 levels in AD patients (324.24±76.38pg/ml) as compared to those in non-AD (NAD) (668.34±43.13pg/ml), neurological controls (NCs) (727.28±46.49pg/ml) and healthy controls (HCs) (976.47±124.46pg/ml). In contrast, hTau and ubiquitin levels were significantly high (568.65±48.89pg/ml and 36.82±4.34ng/ml, respectively) in AD patients compared to those in NAD, NC and HC. The hTau levels were 267.37±36.64pg/ml, 167.34±44.27pg/ml and 107.62±24.27pg/ml in NAD, NC and HC, respectively. Similarly, ubiquitin levels were 23.57±2.32ng/ml, 19.76±3.64ng/ml and 13.24±4.56ng/ml in NAD, NC and HC, respectively. In conclusion, low Aβ42 and high Tau-ubiquitin levels were found in North Indian AD patients.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20599474     DOI: 10.1016/j.neulet.2010.06.075

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

Review 1.  Supplemental substances derived from foods as adjunctive therapeutic agents for treatment of neurodegenerative diseases and disorders.

Authors:  Gregory E Bigford; Gianluca Del Rossi
Journal:  Adv Nutr       Date:  2014-07-14       Impact factor: 8.701

Review 2.  Therapeutics of Neurotransmitters in Alzheimer's Disease.

Authors:  Ramesh Kandimalla; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 3.  Neuroinflammatory Markers: Key Indicators in the Pathology of Neurodegenerative Diseases.

Authors:  Abdur Rauf; Himani Badoni; Tareq Abu-Izneid; Ahmed Olatunde; Md Mominur Rahman; Sakshi Painuli; Prabhakar Semwal; Polrat Wilairatana; Mohammad S Mubarak
Journal:  Molecules       Date:  2022-05-17       Impact factor: 4.927

Review 4.  Neuroinflammation as a Common Feature of Neurodegenerative Disorders.

Authors:  Leonardo Guzman-Martinez; Ricardo B Maccioni; Víctor Andrade; Leonardo Patricio Navarrete; María Gabriela Pastor; Nicolas Ramos-Escobar
Journal:  Front Pharmacol       Date:  2019-09-12       Impact factor: 5.810

5.  CSF p-Tau levels in the prediction of Alzheimer's disease.

Authors:  Ramesh J L Kandimalla; Sudesh Prabhakar; Willayat Yousuf Wani; Alka Kaushal; Nidhi Gupta; Deep Raj Sharma; V K Grover; Neerja Bhardwaj; Kajal Jain; Kiran Dip Gill
Journal:  Biol Open       Date:  2013-09-04       Impact factor: 2.422

Review 6.  Curcumin: a natural substance with potential efficacy in Alzheimer's disease.

Authors:  Pamela E Potter
Journal:  J Exp Pharmacol       Date:  2013-05-02

7.  Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease.

Authors:  Annika Öhrfelt; Per Johansson; Anders Wallin; Ulf Andreasson; Henrik Zetterberg; Kaj Blennow; Johan Svensson
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2016-07-15

Review 8.  Putative Involvement of Endocrine Disruptors in the Alzheimer's Disease Via the Insulin-Regulated Aminopeptidase/GLUT4 Pathway.

Authors:  María Jesús Ramírez-Expósito; Jose Manuel Martínez-Martos; Vanesa Cantón-Habas; María Del Pilar Carrera-González
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.